More threat to Gilead's HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada

Just as GlaxoSmithKline launches an assault at Gilead Sciences’ HIV business in the treatment realm, it’s also targeting the prevention market with new data backing a more convenient alternative to existing offerings.

Gilead’s Truvada won the first FDA nod in 2012 to reduce the risk of HIV infection as a PrEP regimen. Now, GSK has shown its long-acting injectable cabotegravir, given every two months, worked just as well at fending off the virus as Gilead’s daily pill.